Clinical Trials

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Phase 3 Withdrawn

Lymphoma, Follicular, Recurrence

NCT01615029 2026-03-16

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

Phase 1/2 Completed

45 enrolled 14 charts

Multiple Myeloma, Recurrence

NCT03601078 2026-03-04

KarMMa-2

312 enrolled

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT04712097 2026-02-04

Celestimo

478 enrolled

Lymphoma, Follicular, Recurrence

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

300 enrolled

Multiple Myeloma, Recurrence

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07018050 2025-09-22

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Phase 2 Recruiting

160 enrolled

Multiple Myeloma, Recurrence

NCT05626322 2025-09-05

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 1/2 Terminated

6 enrolled 17 charts

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06163040 2025-07-31

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Completed

7 enrolled

Multiple Myeloma, Recurrence

NCT04036448 2025-03-11

RevlimidPMS

Completed

28 enrolled

LymphoidMyeloid

Lymphoma, Follicular, Myelodysplastic Syndromes, Recurrence, Lymphoma, Mantle-Cell

NCT03647124 2025-03-04

A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Completed

105 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT03859427 2024-08-13

ARROW2

454 enrolled 24 charts

Multiple Myeloma, Recurrence, Bone Marrow Neoplasms

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Phase 1 Terminated

4 enrolled

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

NCT02600897 2023-12-26

A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Completed

114 enrolled 34 charts

Lymphoma, Follicular, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Phase 2 Terminated

45 enrolled

Multiple Myeloma, Recurrence

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Phase 1/2 Completed

45 enrolled

Multiple Myeloma, Recurrence

NCT02389543 2023-01-26

SLAM

Phase 1/2 Withdrawn

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT03651128 2022-12-15

KarMMa-3

381 enrolled

Multiple Myeloma, Recurrence

NCT01583283 2022-02-23

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

38 enrolled

Multiple Myeloma, Recurrence

NCT00642954 2020-11-18

MK-0683-074

31 enrolled 13 charts

Multiple Myeloma, Recurrence

NCT02538965 2020-01-07

A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Other hematologic neoplasm

17 enrolled 21 charts

Leukemia, Leukemia, Myeloid, Recurrence, Leukemia, Myeloid, Acute

NCT01197560 2019-11-25

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2/3 Completed

111 enrolled 20 charts

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00065351 2019-11-12

Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

222 enrolled

Multiple Myeloma, Recurrence

NCT02348528 2019-11-12

Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

65 enrolled

Multiple Myeloma, Recurrence

NCT00419250 2019-11-08

A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

52 enrolled

Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00963105 2018-10-31

Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

104 enrolled 18 charts

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00056160 2017-10-19

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

353 enrolled 12 charts

Multiple Myeloma, Recurrence

NCT01359657 2016-03-16

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

46 enrolled

Multiple Myeloma, Recurrence

NCT01160484 2015-05-04

Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma

40 enrolled 15 charts

Multiple Myeloma, Recurrence

NCT00478777 2011-11-03

A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

150 enrolled 9 charts

Multiple Myeloma, Recurrence

NCT00179647 2010-03-16

Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma

1,913 enrolled 8 charts